{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:05Z","timestamp":1786988105194,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Valproic acid (VPA), a widely prescribed mood stabilizer and antiepileptic drug, is frequently associated with metabolic side effects, particularly weight gain. Despite its clinical relevance, the range and diversity of mechanisms underlying VPA-associated weight gain remain incompletely mapped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To map the breadth of evidence on mechanisms of VPA-associated weight gain, characterize the types of studies and populations investigated, and identify knowledge gaps to inform future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This PRISMA-ScR-guided scoping review searched PubMed, Cochrane Library, Scopus, and Google Scholar for studies on VPA-weight gain mechanisms in adults. One reviewer charted data using a piloted form; two independently assessed quality (Newcastle-Ottawa Scale). Sources were grouped by mechanistic pathway with descriptive summaries and vote-counting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,339 participants) were included, representing diverse designs: cross-sectional (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), prospective observational (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), genetic association (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), and others. Evidence mapped to three primary mechanistic domains: hormonal dysregulation (like elevated insulin, leptin, insulin resistance, and other findings); genetic predispositions, including\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      polymorphisms,\n                      <jats:italic>CRTC1<\/jats:italic>\n                      methylation, and other genetic variants; and lipid metabolism alterations (increased TC, LDL-C, TG, FFAs; decreased Apo A1; mixed HDL-C findings). Hormonal and lipid pathways are well-documented, while genetic mechanisms require validation in larger, standardized cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This scoping review identifies a heterogeneous evidence base with well-established hormonal and lipid mechanisms and emerging genetic pathways. Key gaps include underrepresentation of bipolar disorder populations, limited longitudinal genetic studies, and lack of integrated frameworks combining hormonal, genetic, and metabolic data. Findings inform future research priorities and highlight the need for personalized monitoring strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00406-026-02295-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:21:14Z","timestamp":1782217274000},"page":"2759-2768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of weight gain associated with valproic acid: a scoping review"],"prefix":"10.1007","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-1082","authenticated-orcid":false,"given":"Darja","family":"Popkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-3848","authenticated-orcid":false,"given":"Frederike","family":"Fellendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-1335","authenticated-orcid":false,"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-8240","authenticated-orcid":false,"given":"Deniz","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-8021","authenticated-orcid":false,"given":"Aija","family":"Bukova-Zideluna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6553","authenticated-orcid":false,"given":"Eva","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-3674","authenticated-orcid":false,"given":"Nina","family":"Dalkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-5947","authenticated-orcid":false,"given":"Adelina","family":"Tmava-Berisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0638-5389","authenticated-orcid":false,"given":"Melanie","family":"Lenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-6413","authenticated-orcid":false,"given":"Mirko","family":"Manchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-4087","authenticated-orcid":false,"given":"Eva","family":"Reininghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2295_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11940-024-00798-3","volume":"26","author":"C Espinosa-Jovel","year":"2024","unstructured":"Espinosa-Jovel C, Valencia N (2024) The current role of valproic acid in the treatment of epilepsy: a glimpse into the present of an old ally. Curr Treat Options Neurol 26:393\u2013410. https:\/\/doi.org\/10.1007\/s11940-024-00798-3","journal-title":"Curr Treat Options Neurol"},{"key":"2295_CR2","doi-asserted-by":"publisher","unstructured":"Mari J, Dieckmann LHJ, Prates-Baldez D et al (2024) The efficacy of valproate in acute mania, bipolar depression, and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses. BMJ Open 14e087999. https:\/\/doi.org\/10.1136\/bmjopen-2024-087999","DOI":"10.1136\/bmjopen-2024-087999"},{"key":"2295_CR3","first-page":"5734","volume":"24","author":"XY Cui","year":"2020","unstructured":"Cui XY, Sun SM, Liu J et al (2020) The efficacy and safety of valproate medications for migraine in adults: a meta-analysis. Eur Rev Med Pharmacol Sci 24:5734\u20135741","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2295_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004","journal-title":"CNS Drugs"},{"key":"2295_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0404.1984.tb00804.x","volume":"70","author":"H Dinesen","year":"1984","unstructured":"Dinesen H, Gram L, Andersen T et al (1984) Weight gain during treatment with valproate. Acta Neurol Scand 70:65\u201369. https:\/\/doi.org\/10.1111\/j.1600-0404.1984.tb00804.x","journal-title":"Acta Neurol Scand"},{"key":"2295_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","volume":"57","author":"CL Bowden","year":"2000","unstructured":"Bowden CL, Calabrese JR, McElroy SL et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57:481\u2013489. https:\/\/doi.org\/10.1001\/archpsyc.57.5.481","journal-title":"Arch Gen Psychiatry"},{"key":"2295_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.seizure.2006.12.009","volume":"16","author":"F El-Khatib","year":"2007","unstructured":"El-Khatib F, Rauchenzauner M, Lechleitner M et al (2007) Valproate, weight gain and carbohydrate craving: a gender study. Seizure 16:226\u2013232. https:\/\/doi.org\/10.1016\/j.seizure.2006.12.009","journal-title":"Seizure"},{"key":"2295_CR8","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","volume":"12","author":"A Verrotti","year":"2011","unstructured":"Verrotti A, D\u2019Egidio C, Mohn A et al (2011) Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 12:e32\u2013e43. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00800.x","journal-title":"Obes Rev"},{"key":"2295_CR9","doi-asserted-by":"publisher","unstructured":"Abosi O, Lopes S, Schmitz S et al (2018) Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig 36(1). https:\/\/doi.org\/10.1515\/hmbci-2017-0065","DOI":"10.1515\/hmbci-2017-0065"},{"key":"2295_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/ane.12313","volume":"131","author":"RH Aly","year":"2015","unstructured":"Aly RH, Amr NH, Saad WE et al (2015) Insulin resistance in patients on valproic acid: relation to adiponectin. Acta Neurol Scand 131:169\u2013175. https:\/\/doi.org\/10.1111\/ane.12313","journal-title":"Acta Neurol Scand"},{"key":"2295_CR11","doi-asserted-by":"publisher","first-page":"e04553","DOI":"10.1016\/j.heliyon.2020.e04553","volume":"6","author":"N Dolab","year":"2020","unstructured":"Dolab N, Kamkar MZ, Amiriani T et al (2020) The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic acid. Heliyon 6:e04553. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04553","journal-title":"Heliyon"},{"key":"2295_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11055-019-00861-6","volume":"50","author":"AP Drokov","year":"2020","unstructured":"Drokov AP, Lipatova LV, Shnayder NA et al (2020) Pharmacogenetic markers for metabolic impairments in treatment with valproic acid. Neurosci Behav Physiol 50:13\u201319. https:\/\/doi.org\/10.1007\/s11055-019-00861-6","journal-title":"Neurosci Behav Physiol"},{"key":"2295_CR13","doi-asserted-by":"publisher","DOI":"10.21307\/jepil-2018-005","author":"S Jaeri","year":"2018","unstructured":"Jaeri S, Islamiyah WR (2018) The potential mechanisms of effect of valproic acid on lipid profiles: an updated review. J Epileptol. https:\/\/doi.org\/10.21307\/jepil-2018-005","journal-title":"J Epileptol"},{"key":"2295_CR14","doi-asserted-by":"publisher","first-page":"e067516","DOI":"10.1136\/bmj-2021-067516","volume":"376","author":"A Jayedi","year":"2022","unstructured":"Jayedi A, Soltani S, Moltagh SZT et al (2022) Anthropometric and adiposity indicators and risk of type 2 diabetes: systematic review and dose\u2013response meta-analysis of cohort studies. BMJ 376:e067516. https:\/\/doi.org\/10.1136\/bmj-2021-067516","journal-title":"BMJ"},{"key":"2295_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13098-019-0468-0","volume":"11","author":"C Cercato","year":"2019","unstructured":"Cercato C, Fonseca FA (2019) Cardiovascular risk and obesity. Diabetol Metab Syndr 11:74. https:\/\/doi.org\/10.1186\/s13098-019-0468-0","journal-title":"Diabetol Metab Syndr"},{"key":"2295_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1192\/bjp.bp.116.186726","volume":"211","author":"SJ Jung","year":"2017","unstructured":"Jung SJ, Woo HT, Cho S et al (2017) Association between body size, weight change and depression: systematic review and meta-analysis. Br J Psychiatry 211:14\u201321. https:\/\/doi.org\/10.1192\/bjp.bp.116.186726","journal-title":"Br J Psychiatry"},{"key":"2295_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jpsychires.2023.05.034","volume":"163","author":"M Jokela","year":"2023","unstructured":"Jokela M, Laakasuo M (2023) Obesity as a causal risk factor for depression: systematic review and meta-analysis of Mendelian randomization studies and implications for population mental health. J Psychiatr Res 163:86\u201392. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.05.034","journal-title":"J Psychiatr Res"},{"key":"2295_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jad.2023.05.042","volume":"335","author":"C Kraus","year":"2023","unstructured":"Kraus C, Kautzky A, Watzal V et al (2023) Body mass index and clinical outcomes in individuals with major depressive disorder: findings from the GSRD European Multicenter Database. J Affect Disord 335:349\u2013357. https:\/\/doi.org\/10.1016\/j.jad.2023.05.042","journal-title":"J Affect Disord"},{"key":"2295_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1176\/appi.ajp.160.1.112","volume":"160","author":"A Fagiolini","year":"2003","unstructured":"Fagiolini A, Kupfer DJ, Houck PR et al (2003) Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 160:112\u2013117. https:\/\/doi.org\/10.1176\/appi.ajp.160.1.112","journal-title":"Am J Psychiatry"},{"key":"2295_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"key":"2295_CR21","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC et al (2020) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth 18:2119\u20132126. https:\/\/doi.org\/10.11124\/JBIES-20-00167","journal-title":"JBI Evid Synth"},{"key":"2295_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"2295_CR23","unstructured":"Wells GA, Shea B, O\u2019Connell D et al (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2295_CR24","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/s00213-018-4960-2","volume":"235","author":"X Bai","year":"2018","unstructured":"Bai X, Xu C, Wen D et al (2018) Polymorphisms of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients. Psychopharmacology 235:2665\u20132673. https:\/\/doi.org\/10.1007\/s00213-018-4960-2","journal-title":"Psychopharmacology"},{"key":"2295_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13148-019-0792-0","volume":"11","author":"A Delacr\u00e9taz","year":"2019","unstructured":"Delacr\u00e9taz A, Glatard A, Dubath C et al (2019) Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients. Clin Epigenetics 11:198. https:\/\/doi.org\/10.1186\/s13148-019-0792-0","journal-title":"Clin Epigenetics"},{"key":"2295_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bcpt.13580","volume":"129","author":"A Delacr\u00e9taz","year":"2021","unstructured":"Delacr\u00e9taz A, Glatard A, Dubath C et al (2021) Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. Basic Clin Pharmacol Toxicol 129:26\u201335. https:\/\/doi.org\/10.1111\/bcpt.13580","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2295_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/17512433.2016.113112","volume":"9","author":"SA Hamed","year":"2016","unstructured":"Hamed SA, Fathy RA, Radwan ME et al (2016) Fatty liver in adults receiving antiepileptic medications: relationship to the metabolic risks. Expert Rev Clin Pharmacol 9:617\u2013624. https:\/\/doi.org\/10.1586\/17512433.2016.113112","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2295_CR28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.15562\/bmj.v11i3.3748","volume":"11","author":"WR Islamiyah","year":"2022","unstructured":"Islamiyah WR, Nasronudin, Machin A et al (2022) Relationship between CYP2C19 polymorphisms and weight gain in epilepsy patients treated with divalproex sodium: does gender matter? Bali Med J 11:1800\u20131804. https:\/\/doi.org\/10.15562\/bmj.v11i3.3748","journal-title":"Bali Med J"},{"key":"2295_CR29","doi-asserted-by":"publisher","first-page":"pyv021","DOI":"10.1093\/ijnp\/pyv021","volume":"18","author":"H Li","year":"2015","unstructured":"Li H, Wang X, Zhou Y et al (2015) Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. Int J Neuropsychopharmacol 18:pyv021. https:\/\/doi.org\/10.1093\/ijnp\/pyv021","journal-title":"Int J Neuropsychopharmacol"},{"key":"2295_CR30","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1111\/jcmm.14464","volume":"23","author":"R Li","year":"2019","unstructured":"Li R, Qin X, Liang X et al (2019) Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid. J Cell Mol Med 23:6017\u20136023. https:\/\/doi.org\/10.1111\/jcmm.14464","journal-title":"J Cell Mol Med"},{"key":"2295_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fnut.2019.00076","volume":"6","author":"H Mangge","year":"2019","unstructured":"Mangge H, Bengesser S, Dalkner N et al (2019) Weight gain during treatment of bipolar disorder (BD)\u2014facts and therapeutic options. Front Nutr 6:76. https:\/\/doi.org\/10.3389\/fnut.2019.00076","journal-title":"Front Nutr"},{"key":"2295_CR32","doi-asserted-by":"publisher","first-page":"106786","DOI":"10.1016\/j.eplepsyres.2021.106786","volume":"177","author":"M Balachandran","year":"2021","unstructured":"Balachandran M, Nair PP, Sekhar A et al (2021) CYP2C19 & UGT1A6 genetic polymorphisms and the impact on valproic acid-induced weight gain in people with epilepsy: prospective genetic association study. Epilepsy Res 177:106786. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106786","journal-title":"Epilepsy Res"},{"key":"2295_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.seizure.2024.08.003","volume":"121","author":"SC Sarangi","year":"2024","unstructured":"Sarangi SC, Pattnaik SS, Dash Y et al (2024) Is there any concern of insulin resistance and metabolic dysfunctions with antiseizure medications? A prospective comparative study of valproate vs. levetiracetam. Seizure 121:123\u2013132. https:\/\/doi.org\/10.1016\/j.seizure.2024.08.003","journal-title":"Seizure"},{"key":"2295_CR34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/biomedicines11051499","volume":"11","author":"NA Shnayder","year":"2023","unstructured":"Shnayder NA, Grechkina VV, Trefilova VV et al (2023) Valproate-induced metabolic syndrome. Biomedicines 11:1499. https:\/\/doi.org\/10.3390\/biomedicines11051499","journal-title":"Biomedicines"},{"key":"2295_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.seizure.2017.03.007","volume":"48","author":"HS Sidhu","year":"2017","unstructured":"Sidhu HS, Srinivas R, Sadhotra A (2017) Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: a prospective study. Seizure 48:15\u201321. https:\/\/doi.org\/10.1016\/j.seizure.2017.03.007","journal-title":"Seizure"},{"key":"2295_CR36","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s13760-020-01552-7","volume":"121","author":"F \u015eim\u015fek","year":"2021","unstructured":"\u015eim\u015fek F, Ceylan M, K\u0131z\u0131ltun\u00e7 A et al (2021) The correlation between carbamazepine and valproic acid monotherapy with serum adiponectin and carnitine. Acta Neurol Belg 121:1823\u20131830. https:\/\/doi.org\/10.1007\/s13760-020-01552-7","journal-title":"Acta Neurol Belg"},{"key":"2295_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00228-022-03279-1","volume":"78","author":"AM Yaryari","year":"2022","unstructured":"Yaryari AM, Mazdeh M, Mohammadi M et al (2022) Evaluation of serum levels of asprosin and other metabolic profiles in patients with idiopathic tonic-clonic generalized epilepsy on treatment with valproic acid. Eur J Clin Pharmacol 78:393\u2013403. https:\/\/doi.org\/10.1007\/s00228-022-03279-1","journal-title":"Eur J Clin Pharmacol"},{"key":"2295_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/ane.12473","volume":"133","author":"M Noai","year":"2016","unstructured":"Noai M, Soraoka H, Kajiwara A et al (2016) Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand 133:216\u2013223. https:\/\/doi.org\/10.1111\/ane.12473","journal-title":"Acta Neurol Scand"},{"key":"2295_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0304-4165(90)90079-C","volume":"1034","author":"M Ito","year":"1990","unstructured":"Ito M, Ikeda Y, Arnez JG et al (1990) The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 1034:213\u2013218. https:\/\/doi.org\/10.1016\/0304-4165(90)90079-C","journal-title":"Biochim Biophys Acta"},{"key":"2295_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","volume":"107","author":"V Belcastro","year":"2013","unstructured":"Belcastro V, D\u2019Egidio C, Striano P et al (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107:1\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.08.016","journal-title":"Epilepsy Res"},{"key":"2295_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/toxsci\/kfi185","volume":"86","author":"V Tong","year":"2005","unstructured":"Tong V, Teng XW, Chang TKH et al (2005) Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 86:436\u2013443. https:\/\/doi.org\/10.1093\/toxsci\/kfi185","journal-title":"Toxicol Sci"},{"key":"2295_CR42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3389\/fendo.2019.00540","volume":"10","author":"M Di Domenico","year":"2019","unstructured":"Di Domenico M, Pinto F, Quagliuolo L et al (2019) The role of oxidative stress and hormones in controlling obesity. Front Endocrinol 10:540. https:\/\/doi.org\/10.3389\/fendo.2019.00540","journal-title":"Front Endocrinol"},{"key":"2295_CR43","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere C, Duerrschmid C, Bournat J et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165:566\u2013579. https:\/\/doi.org\/10.1016\/j.cell.2016.02.063","journal-title":"Cell"},{"key":"2295_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","volume":"19","author":"BB Barton","year":"2020","unstructured":"Barton BB, Segger F, Fischer K et al (2020) Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf 19:295\u2013314. https:\/\/doi.org\/10.1080\/14740338.2020.1713091","journal-title":"Expert Opin Drug Saf"},{"key":"2295_CR45","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/epi.12745","volume":"55","author":"SJ Petty","year":"2014","unstructured":"Petty SJ, Kantor S, Lawrence KM et al (2014) Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study. Epilepsia 55:1551\u20131557. https:\/\/doi.org\/10.1111\/epi.12745","journal-title":"Epilepsia"},{"key":"2295_CR46","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.yfrne.2022.101013","volume":"67","author":"B Misiak","year":"2022","unstructured":"Misiak B, Kowalski K, Sta\u0144czykiewicz B et al (2022) Appetite-regulating hormones in bipolar disorder: a systematic review and meta-analysis. Front Neuroendocrinol 67:101013. https:\/\/doi.org\/10.1016\/j.yfrne.2022.101013","journal-title":"Front Neuroendocrinol"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02295-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:01:25Z","timestamp":1786986085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02295-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02295-x","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}